KR950000158A - Use of attenuated Pseudomonas aeruginosa CFCPA 20215 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections - Google Patents
Use of attenuated Pseudomonas aeruginosa CFCPA 20215 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections Download PDFInfo
- Publication number
- KR950000158A KR950000158A KR1019930010275A KR930010275A KR950000158A KR 950000158 A KR950000158 A KR 950000158A KR 1019930010275 A KR1019930010275 A KR 1019930010275A KR 930010275 A KR930010275 A KR 930010275A KR 950000158 A KR950000158 A KR 950000158A
- Authority
- KR
- South Korea
- Prior art keywords
- pseudomonas aeruginosa
- attenuated
- cfcpa
- agent
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
본 발명은 피셔―데블린 면역형태에 따라 타입 2의 녹농균을 순수하게 분리하여 반복적으로 순화시킴으로써 약독화시켜 수득되는 신규의 안전한 약독화 녹농균주 CFCPA 20215(KCCM 10030)의 녹농균 감염증 치료제 및 예방용 백신의 제조를 위한 용도에 관한 것이다.The present invention provides a novel safe attenuated Pseudomonas aeruginosa CFCPA 20215 (KCCM 10030) obtained by attenuating by purely separating and repeatedly purifying Pseudomonas aeruginosa of type 2 according to the Fischer-Deblin immunomorphology of the vaccine for the treatment and prevention of Pseudomonas aeruginosa infections. It relates to a use for the production.
본 발명에서 이용되는 신규한 약독화 녹농균주 CFCPA 20215(KCCM 10030)는 독성이 없이 안전하며, 그의 세포벽 단백질 성분도 안전하면서도 우수한 항체 생성능을 나타내고, 또한 이들로부터 구성되는 본 발명에 따르는 녹농균 감염 예방 백신 및 녹농균 감염증 치료제는 피셔 면역형 2뿐 아니라 3 및 7의 녹농균주에 대해서도 탁월한 교차방어 능력을 나타낸다.The novel attenuated Pseudomonas aeruginosa CFCPA 20215 (KCCM 10030) used in the present invention is safe without toxicity, its cell wall protein components are safe and exhibit excellent antibody-producing ability, and are also composed of the Pseudomonas aeruginosa infection prevention vaccine according to the present invention. Pseudomonas aeruginosa infectious agents show excellent cross-protection ability against Pseudomonas aeruginosa strains 3 and 7 as well as Fischer immunotype 2.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930010275A KR970001704B1 (en) | 1993-06-07 | 1993-06-07 | Pseudomonas infection preventing vaccines using attenuated pseudomonas cfcpa 20215 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930010275A KR970001704B1 (en) | 1993-06-07 | 1993-06-07 | Pseudomonas infection preventing vaccines using attenuated pseudomonas cfcpa 20215 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR950000158A true KR950000158A (en) | 1995-01-03 |
KR970001704B1 KR970001704B1 (en) | 1997-02-14 |
Family
ID=19356960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930010275A KR970001704B1 (en) | 1993-06-07 | 1993-06-07 | Pseudomonas infection preventing vaccines using attenuated pseudomonas cfcpa 20215 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR970001704B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017150849A1 (en) * | 2016-03-03 | 2017-09-08 | 아이진 주식회사 | Attenuated pseudomonas aeruginosa improved in productivity and safety and vaccine composition comprising same |
-
1993
- 1993-06-07 KR KR1019930010275A patent/KR970001704B1/en not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017150849A1 (en) * | 2016-03-03 | 2017-09-08 | 아이진 주식회사 | Attenuated pseudomonas aeruginosa improved in productivity and safety and vaccine composition comprising same |
KR20170103330A (en) * | 2016-03-03 | 2017-09-13 | 아이진 주식회사 | Attenuated Pseudomonas aeruginosa Having Improved Productivity and Safety, and Vaccine Composition Comprising the Same |
Also Published As
Publication number | Publication date |
---|---|
KR970001704B1 (en) | 1997-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2293470A1 (en) | Benzimidazole derivatives | |
RU94041223A (en) | Agent for motoneuron disease treatment | |
FR2762843B1 (en) | NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CA2094137A1 (en) | Novel hydroxamic acid and n-hydroxyurea derivatives and their use | |
IL111674A0 (en) | 5,6-Dihydropyrone derivatives and pharmaceutical compositions containing them | |
IL111673A0 (en) | 5,6-Dihydropyrone derivatives and pharmaceutical compositions containing them | |
AU3453493A (en) | Pharmaceutical preparation based on rhamnolipid against dermatological diseases, e.g. papilloma virus infections | |
KR950000158A (en) | Use of attenuated Pseudomonas aeruginosa CFCPA 20215 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections | |
SE9500418L (en) | New attenuated Pseudomonas aerugionos strains | |
Ismail et al. | The ocular effects of spitting cobras: I. The ringhals cobra (Hemachatus haemachatus) venom-induced corneal opacification syndrome | |
KR950000157A (en) | Use of attenuated Pseudomonas aeruginosa CFCPA 10142 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections | |
KR950000161A (en) | Use of attenuated Pseudomonas aeruginosa CFCPA 50243 for the manufacture of a therapeutic and preventive vaccine for Pseudomonas aeruginosa infections | |
KR950000159A (en) | Use of attenuated Pseudomonas aeruginosa CFCPA 30720 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections | |
KR950000162A (en) | Use of attenuated Pseudomonas aeruginosa CFCPA 60534 for the manufacture of a therapeutic and preventive vaccine for Pseudomonas aeruginosa infections | |
KR950000163A (en) | Use of attenuated Pseudomonas aeruginosa CFCPA 70018 for the manufacture of a therapeutic and preventive vaccine for Pseudomonas aeruginosa infections | |
KR950000160A (en) | Use of attenuated Pseudomonas aeruginosa CFCPA 40057 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections | |
KR960700711A (en) | Medicine for treating or preventing cerebrovascular diseases | |
CA2065889A1 (en) | Increasing the choroidal blood flow | |
KR950000164A (en) | Pseudomonas aeruginosa infectious agent and its manufacturing method | |
AR004507A1 (en) | A TROVAFLOXACIN PROPHARMAC, A PROCEDURE TO TREAT A BACTERIAL INFECTION IN A MAMMAL THROUGH THE SAME, A PARAPREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION THAT UNDERSTAND IT | |
DK0728002T3 (en) | Use of 2-aminopurine derivatives for the treatment and prevention of human herpes virus 7 infections | |
RU94020944A (en) | Agent for intranasal influenza prophylaxis | |
CA2193665A1 (en) | Benzimidazole derivatives for the treatment and prophylaxis of virus infections | |
DK0728001T3 (en) | Use of 2-aminopurine derivatives for the treatment and prevention of human herpes virus 6 infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080626 Year of fee payment: 12 |
|
LAPS | Lapse due to unpaid annual fee |